Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Supplemental material
  • Version history
  • Article usage
  • Citations to this article

Advertisement

ResearchIn-Press PreviewDevelopmentGastroenterologyOncology Open Access | 10.1172/JCI197772

Multiomic analyses delineate human neuroendocrine tumor cell states in relation to normal enteroendocrine cell ontogeny

Pratik N.P. Singh,1 Elsa Hadj Bachir,1 James R. Howe,2 Andrew M. Bellizzi,3 Paloma Cejas,4 Shariq Madha-Krause,1 Charles B. Epstein,5 Jennifer Chan,1 Bradley E. Bernstein,5 Matthew H. Kulke,1 Qiao Zhou,6 and Ramesh A. Shivdasani1

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, United States of America

3Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, United States of America

4Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States of America

5Epigenomics Program, Broad Institute of Harvard and MIT, Cambridge, United States of America

6Division of Regenerative Medicine and Hartman Institute for Therapeutic Org, Weill Cornell Medicine, New York, United States of America

Find articles by Singh, P. in: PubMed | Google Scholar

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, United States of America

3Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, United States of America

4Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States of America

5Epigenomics Program, Broad Institute of Harvard and MIT, Cambridge, United States of America

6Division of Regenerative Medicine and Hartman Institute for Therapeutic Org, Weill Cornell Medicine, New York, United States of America

Find articles by Hadj Bachir, E. in: PubMed | Google Scholar

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, United States of America

3Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, United States of America

4Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States of America

5Epigenomics Program, Broad Institute of Harvard and MIT, Cambridge, United States of America

6Division of Regenerative Medicine and Hartman Institute for Therapeutic Org, Weill Cornell Medicine, New York, United States of America

Find articles by Howe, J. in: PubMed | Google Scholar

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, United States of America

3Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, United States of America

4Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States of America

5Epigenomics Program, Broad Institute of Harvard and MIT, Cambridge, United States of America

6Division of Regenerative Medicine and Hartman Institute for Therapeutic Org, Weill Cornell Medicine, New York, United States of America

Find articles by Bellizzi, A. in: PubMed | Google Scholar

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, United States of America

3Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, United States of America

4Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States of America

5Epigenomics Program, Broad Institute of Harvard and MIT, Cambridge, United States of America

6Division of Regenerative Medicine and Hartman Institute for Therapeutic Org, Weill Cornell Medicine, New York, United States of America

Find articles by Cejas, P. in: PubMed | Google Scholar |

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, United States of America

3Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, United States of America

4Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States of America

5Epigenomics Program, Broad Institute of Harvard and MIT, Cambridge, United States of America

6Division of Regenerative Medicine and Hartman Institute for Therapeutic Org, Weill Cornell Medicine, New York, United States of America

Find articles by Madha-Krause, S. in: PubMed | Google Scholar

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, United States of America

3Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, United States of America

4Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States of America

5Epigenomics Program, Broad Institute of Harvard and MIT, Cambridge, United States of America

6Division of Regenerative Medicine and Hartman Institute for Therapeutic Org, Weill Cornell Medicine, New York, United States of America

Find articles by Epstein, C. in: PubMed | Google Scholar

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, United States of America

3Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, United States of America

4Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States of America

5Epigenomics Program, Broad Institute of Harvard and MIT, Cambridge, United States of America

6Division of Regenerative Medicine and Hartman Institute for Therapeutic Org, Weill Cornell Medicine, New York, United States of America

Find articles by Chan, J. in: PubMed | Google Scholar

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, United States of America

3Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, United States of America

4Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States of America

5Epigenomics Program, Broad Institute of Harvard and MIT, Cambridge, United States of America

6Division of Regenerative Medicine and Hartman Institute for Therapeutic Org, Weill Cornell Medicine, New York, United States of America

Find articles by Bernstein, B. in: PubMed | Google Scholar

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, United States of America

3Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, United States of America

4Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States of America

5Epigenomics Program, Broad Institute of Harvard and MIT, Cambridge, United States of America

6Division of Regenerative Medicine and Hartman Institute for Therapeutic Org, Weill Cornell Medicine, New York, United States of America

Find articles by Kulke, M. in: PubMed | Google Scholar

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, United States of America

3Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, United States of America

4Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States of America

5Epigenomics Program, Broad Institute of Harvard and MIT, Cambridge, United States of America

6Division of Regenerative Medicine and Hartman Institute for Therapeutic Org, Weill Cornell Medicine, New York, United States of America

Find articles by Zhou, Q. in: PubMed | Google Scholar

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States of America

2Department of Surgery, Carver College of Medicine, University of Iowa, Iowa City, United States of America

3Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, United States of America

4Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States of America

5Epigenomics Program, Broad Institute of Harvard and MIT, Cambridge, United States of America

6Division of Regenerative Medicine and Hartman Institute for Therapeutic Org, Weill Cornell Medicine, New York, United States of America

Find articles by Shivdasani, R. in: PubMed | Google Scholar

Published May 21, 2026 - More info

J Clin Invest. https://doi.org/10.1172/JCI197772.
Copyright © 2026, Singh et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published May 21, 2026 - Version history
View PDF
Abstract

Cancers reflect aberrant growth and differentiation of normal cell populations. Biological understanding of small intestine neuroendocrine tumors (SI-NETs) is hampered because their closest normal counterparts, enteroendocrine cells (EECs), constitute tiny fractions of intestinal epithelium. Recent characterization of adult human EEC ontogeny from intestinal stem cells can help overcome that limitation. Transient expression of transcription factor gene ASCL1 normally ensures proper timing and fidelity of well-differentiated EECs, which express NEUROD1. Here we report that SI-NETs resembled mature enterochromaffin cells; however, individual tumor cells co-expressed stem/progenitor genes, harboring each differentiation state along the EEC trajectory except ASCL1+ precursors. We found that enhancers normally active, and others inactive, during EEC differentiation underlie aberrant SI-NET gene activity. SI-NETs uniformly expressed NEUROD1 but lacked ASCL1, owing to inaccessible chromatin and repressive H3K27me3 marking at the ASCL1 locus. Multiple cyclin-dependent kinase inhibitor (CDKi) genes were similarly silenced, other than CDKN1B, the only gene recurrently mutated in SI-NETs. Deletion of CDKN1B altered cell cycle kinetics during human EEC differentiation, and deletions of ASCL1 or CDKN1B activated certain genes that are expressed in SI-NETs but not in the normal EEC trajectory. We propose that a limited CDKi repertoire and absence of ASCL1-dependent constraints on EEC maturation together explain unique SI-NET characteristics.

Graphical Abstract
graphical abstract
Supplemental material

View

Version history
  • Version 1 (May 21, 2026): In-Press Preview

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts